Max and Lillie Sonnenberg Doctoral Conference Travel Grant — Round 2, 2026
Round 2 is open for doctoral researchers presenting at in-person conferences between November 2026 and April 2027. Applications close on 4 October 2026 through UCT’s PeopleSoft Student Portal. Awards contribute to travel, registration and conference-day subsistence. Local and specified SADC conference support is capped at ZAR 10,000; the overall maximum is ZAR 32,000. The grant does not normally fund the full trip. Applicants must secure remaining costs, provide proof of paper acceptance before payment and submit a post-conference report. At most one local and one international grant may be awarded per applicant in a calendar year within the overall limit.
Hughlings Jackson Lecture: Making Progress in Progressive MS – the Ultimate Challenge!
On April 22, 2021, Dr. Alan J Thompson of the University College London and the UCL Institute of Neurology, London, UK will deliver the Hughlings Jackson Lecture entitled, “Making Progress in Progressive MS – the Ultimate Challenge!” Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honors the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the development of neurology as a medical specialty. Talk Abstract : The international focus on progressive MS, driven by the Progressive MS Alliance amongst others, together with recent encouraging results from clinical trials have raised the profile and emphasised the importance of understanding, treating and ultimately preventing progression in MS. Effective treatment for Progressive MS is now regarded as the single most important issue facing the MS community. There are several important challenges to developing new treatments for progressive MS. Fundamental to any development in treatment is a better understanding of the mechanisms of tissue injury underpinning progression which will in turn allow the identification of new targets against which treatments can be directed. There are additional complications in determining when progression actually starts, determining the impact of aging and defining the progressive clinical phenotypes – an area which has become increasingly complex in recent months. Evaluating potential new treatments in progressive MS also poses particular challenges including trial design and the selection of appropriate clinical and imaging outcomes - in particular, identifying an imaging biomarker for phase II trials of progressive MS. Despite these challenges, considerable progress is being made in developing new treatments targeting the innate immune system and exploring neuroprotective strategies. Further advances are being driven by a number of international networks, funded by the Progressive MS Alliance. Overall we are seeing encouraging progress as a result of co-ordinated global collaboration which offers real possibilities for truly effective treatment of progression.
Sensory-motor control, cognition and brain evolution: exploring the links
Drawing on recent findings from evolutionary anthropology and neuroscience, professor Barton will lead us through the amazing story of the evolution of human cognition. Usingstatistical, phylogenetic analyses that tease apart the variation associated with different neural systems and due to different selection pressures, he will be addressing intriguing questions like ‘Why are there so many neurons in the cerebellum?’, ‘Is the neocortex the ‘intelligent’ bit of the brain?’, and ‘What explains that the recognition by humans of emotional expressions is disrupted by trancranial magnetic stimulation of the somatosensory cortex?’ Could, as professor Barton suggests, the cerebellum -modestly concealed beneath the volumetrically dominating neocortex and largely ignored- turn out to be the Cinderella of the study of brain evolution?